Fuji Pharma Co. Ltd
Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women, in vitro diagnostics, acute medical care products, and curative medicines, and information regarding pharmace… Read more
Fuji Pharma Co. Ltd (FUP) - Total Liabilities
Latest total liabilities as of September 2025: €46.50 Billion EUR
Based on the latest financial reports, Fuji Pharma Co. Ltd (FUP) has total liabilities worth €46.50 Billion EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Fuji Pharma Co. Ltd - Total Liabilities Trend (2014–2025)
This chart illustrates how Fuji Pharma Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Fuji Pharma Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Fuji Pharma Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Comintel Corporation Berhad
KLSE:7195
|
Malaysia | RM807.08 Million |
|
Lict Corporation
PINK:LICT
|
USA | $140.84 Million |
|
PetroVietnam General Services Corp
VN:PET
|
Vietnam | ₫10.90 Trillion |
|
Fundamental Global Inc.
NASDAQ:FGNXP
|
USA | $13.72 Million |
|
BioInvent International AB (publ)
PINK:BOVNF
|
USA | $102.10 Million |
|
BANPU POWER
BK:BPP-R
|
Thailand | ฿42.69 Billion |
|
JETEMA Co. Ltd
KQ:216080
|
Korea | ₩156.25 Billion |
|
Reservoir Media Inc
NASDAQ:RSVR
|
USA | $567.10 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Fuji Pharma Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.99 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fuji Pharma Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fuji Pharma Co. Ltd (2014–2025)
The table below shows the annual total liabilities of Fuji Pharma Co. Ltd from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | €46.50 Billion | +4.64% |
| 2024-09-30 | €44.44 Billion | +0.64% |
| 2023-09-30 | €44.16 Billion | +11.13% |
| 2022-09-30 | €39.73 Billion | +25.91% |
| 2021-09-30 | €31.56 Billion | +43.44% |
| 2020-09-30 | €22.00 Billion | +2.94% |
| 2019-09-30 | €21.37 Billion | +20.29% |
| 2018-09-30 | €17.77 Billion | +4.82% |
| 2017-09-30 | €16.95 Billion | -10.41% |
| 2016-09-30 | €18.92 Billion | +10.14% |
| 2015-09-30 | €17.18 Billion | -16.13% |
| 2014-09-30 | €20.48 Billion | -- |